TB-500 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-16 and is reviewed periodically as new material appears.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
==== Trinidad and Tobago ==== The destroyer Gravely arrived on 26 October 2025 to spend four days in Trinidad and Tobago, where their country's forces would jointly train with US Marines. Trinidad and Tobago announced additional joint training drills with US Marines in November. Caine would travel to Trinidad and Tobago after the November 2025 Puerto Rico visit to meet with Trinidad and Tobago Prime Minister Kamla Persad-Bissessar; the Caribbean National Weekly stated that the visit came "as the two nations deepen their security collaboration to strengthen regional stability and combat illicit trafficking and transnational criminal organizations". In late November, the US installed a radar system in the island nation, which is useful for aerial surveillance. In December, Trinidad and Tobago approved military aircraft from the US to use the country's airports for operations that are "logistical in nature, facilitating supply replenishment and routing personnel rotations", according to its foreign ministry.
=== Space science and planetary research === Space science and planetary research at the University of Arizona are largely conducted through the Lunar and Planetary Laboratory (LPL), which has led or contributed to numerous NASA missions. The university received more than $325 million for the LPL to lead NASA's 2007–08 Phoenix Mars Mission, which explored the Martian Arctic. It later received another $800 million for the OSIRIS-REx mission, the first mission in U.S. history to collect a sample from an asteroid. The LPL's contributions to the Cassini mission orbiting Saturn were larger than those of any other university in the world. University researchers designed and operated the spacecraft's atmospheric radiation and imaging investigations. The university also operates the HiRISE camera aboard the Mars Reconnaissance Orbiter. The spacecraft reached Mars in March 2006 after traveling 300 million miles. The University of Arizona-designed camera was led by planetary scientist Alfred McEwen, the project's principal investigator. HiRISE captured high-resolution images of the planet. In 2011, University of Arizona alumnus and planetary scientist Lujendra Ojha and his research team used HiRISE imagery to identify evidence of liquid water on the surface of Mars. NASA confirmed the discovery in 2015. The university receives more NASA grants annually than the next nine top NASA-Jet Propulsion Laboratory-funded universities combined. In August 2007, the University of Arizona, under the direction of planetary scientist Peter Smith, led the Phoenix Mars Mission.
=== Exposure-response === Exposure-Response models establish the relationship between drug exposure and clinical response. They play a crucial role in determining the optimal therapeutic range and predicting the likelihood of efficacy or adverse events. These models not only guide dose individualization based on desired clinical outcomes but also provide information on population exposure-response relationships for effects and adverse effects.
== See also == Common beta emitters Neutrino Betavoltaics Particle radiation Radionuclide Tritium illumination, a form of fluorescent lighting powered by beta decay Pandemonium effect Total absorption spectroscopy
Sources: en.wikipedia.org
=== Rate === In contrast to the accepted Occupation Theory, Rate Theory proposes that the activation of receptors is directly proportional to the total number of encounters of a drug with its receptors per unit time. Pharmacological activity is directly proportional to the rates of dissociation and association, not the number of receptors occupied:
Both 123I and 125I emit copious low energy Auger electrons after their decay, but these do not cause serious damage (double-stranded DNA breaks) in cells, unless the nuclide is incorporated into a medication that accumulates in the nucleus, or into DNA (this is never the case is clinical medicine, but it has been seen in experimental animal models). Iodine-125 is also commonly used by radiation oncologists in low dose rate brachytherapy in the treatment of cancer at sites other than the thyroid, especially in prostate cancer. When 125I is used therapeutically, it is encapsulated in titanium seeds and implanted in the area of the tumor, where it remains. The low energy of the gamma spectrum in this case limits radiation damage to tissues far from the implanted capsule. Iodine-125, due to its suitable longer half-life and less penetrating gamma spectrum, is also often preferred for laboratory tests that rely on iodine as a tracer that is counted by a gamma counter, such as in radioimmunoassaying. 125I is used as the radiolabel in investigating which ligands go to which plant pattern recognition receptors (PRRs).
=== Cancer risk === Studies are mixed on whether the risk of breast cancer is increased with hormone therapy in transgender women. Two cohort studies found no increase in risk relative to cisgender men, whereas another cohort study found an almost 50-fold increase in risk such that the incidence of breast cancer was between that of cisgender men and cisgender women. There is no evidence that breast cancer risk in transgender women is greater than in cisgender women. Twenty cases of breast cancer in transgender women have been reported as of 2019. Cisgender men with gynecomastia have not been found to have an increased risk of breast cancer. It has been suggested that a 46,XY karyotype (one X chromosome and one Y chromosome) may be protective against breast cancer compared to having a 46,XX karyotype (two X chromosomes). Men with Klinefelter's syndrome (47,XXY karyotype), which causes hypoandrogenism, hyperestrogenism, and a very high incidence of gynecomastia (80%), have a dramatically (20- to 58-fold) increased risk of breast cancer compared to karyotypical men (46,XY), closer to the rate of karyotypical women (46,XX). The incidences of breast cancer in karyotypical men, men with Klinefelter's syndrome, and karyotypical women are approximately 0.1%, 3%, and 12.5%, respectively. Women with complete androgen insensitivity syndrome (46,XY karyotype) never develop male sex characteristics and have normal and complete female morphology, including breast development, yet have not been reported to develop breast cancer.
== History == Dino Martin, Desi Arnaz Jr. and Billy Hinsche first met in grammar school. Due to the family connections of Dino and Desi, the band's first audition was for Frank Sinatra, who founded and still had an interest in Reprise Records, the recording label for Dean Martin. Though Arnaz, whose father was a famous drummer and who had learned to play drums from close family friend Richard Keith (who played Little Ricky on I Love Lucy) was a skilled drummer in his own right, the group did not play their own instruments on most of their records, instead using top session players, producers and songwriters. Producers included Lee Hazlewood, Billy Strange and Jimmy Bowen. Songwriters whose compositions were recorded by the group included Hazlewood, Red West, David Gates, Boyce and Hart, Clint Ballard Jr. and Bonner & Gordon. Dino, Desi & Billy's best known songs were "I'm a Fool" (1965; U.S. Billboard Hot 100 No. 17; later covered by Alvin and the Chipmunks for their 1965 album Chipmunks à Go-Go) and "Not the Lovin' Kind" (1965; U.S. No. 25). Both were hits for the group before any group member had reached the age of 15. Following this success, in 1965, they toured as an opening act for the Beach Boys. The group also opened for Paul Revere & the Raiders, Tommy Roe, Sam the Sham, the Lovin' Spoonful and the Mamas & the Papas. The band did not have a top 40 hit after 1965, despite releasing records for five years thereafter.
=== Prussian Blue === Prussian Blue, also known as Berlin Blue, Paris Blue, or Turnbull's Blue, is an inorganic pigment, produced in large quantities for both artistic purposes and textiles. It has the chemical formula FeIII4[FeII(CN)6]3. With a history dating back to the early 18th century, Prussian blue remains a popular artistic pigment. Studies of Prussian Blue lead to discoveries about hydrogen cyanide. It is an antidote for heavy metal poisoning, and is famed for being used to color the uniforms of the Prussian army in the 18th century.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.